Does the media favor CRDL or ZVRA?

In the previous week, Zevra Therapeutics had 27 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 30 mentions for Zevra Therapeutics and 3 mentions for Cardiol Therapeutics. Zevra Therapeutics' average media sentiment score of 0.41 beat Cardiol Therapeutics' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zevra Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, CRDL or HELP?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A Cybin N/A N/A -$148M -$4.23 N/A

Is CRDL or HELP more profitable?

Cybin's return on equity of -68.27% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Cybin N/A -68.27% -58.26%

Does the media prefer CRDL or HELP?

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 3 articles in the media. Cybin's average media sentiment score of 0.40 beat Cardiol Therapeutics' score of 0.00 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CRDL or CRMD?

In the previous week, Cardiol Therapeutics had 1 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Cardiol Therapeutics' score of 0.00 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CRDL or CTNM more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Contineum Therapeutics N/A -24.73% -23.51%

Does the media prefer CRDL or CTNM?

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 1 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.61 beat Cardiol Therapeutics' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, CRDL or RLMD?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is CRDL or RLMD more profitable?

Relmada Therapeutics' return on equity of -59.03% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Relmada Therapeutics N/A -59.03% -53.97%

Does the media prefer CRDL or RLMD?

In the previous week, Relmada Therapeutics had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 7 mentions for Relmada Therapeutics and 3 mentions for Cardiol Therapeutics. Relmada Therapeutics' average media sentiment score of 0.53 beat Cardiol Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Cardiol Therapeutics (CRDL) Competitors

$1.44 +0.03 (+1.76%)

As of 02:44 PM Eastern

Compare

CRDL vs. ZVRA, HELP, CRMD, CTNM, and RLMD

Should you buy Cardiol Therapeutics stock or one of its competitors? MarketBeat compares Cardiol Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiol Therapeutics include Zevra Therapeutics (ZVRA), Cybin (HELP), CorMedix (CRMD), Contineum Therapeutics (CTNM), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceuticals" industry.

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Zevra Therapeutics has a net margin of 42.82% compared to Cardiol Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Zevra Therapeutics	42.82%	54.54%	34.15%

In the previous week, Zevra Therapeutics had 27 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 30 mentions for Zevra Therapeutics and 3 mentions for Cardiol Therapeutics. Zevra Therapeutics' average media sentiment score of 0.41 beat Cardiol Therapeutics' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zevra Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardiol Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zevra Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Zevra Therapeutics	$106.47M	6.32	$83.23M	$0.92	12.32

Cardiol Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 488.24%. Zevra Therapeutics has a consensus price target of $27.14, indicating a potential upside of 139.46%. Given Cardiol Therapeutics' higher possible upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Zevra Therapeutics beats Cardiol Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Cybin?

Cardiol Therapeutics (NASDAQ:CRDL) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Cybin has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 3 articles in the media. Cybin's average media sentiment score of 0.40 beat Cardiol Therapeutics' score of 0.00 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardiol Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 488.24%. Cybin has a consensus target price of $45.25, indicating a potential upside of 342.28%. Given Cardiol Therapeutics' higher probable upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Cybin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cybin's return on equity of -68.27% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Cybin	N/A	-68.27%	-58.26%

Summary

Cybin beats Cardiol Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Cardiol Therapeutics compare to CorMedix?

Cardiol Therapeutics (NASDAQ:CRDL) and CorMedix (NASDAQ:CRMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Cardiol Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 488.24%. CorMedix has a consensus price target of $14.86, indicating a potential upside of 99.02%. Given Cardiol Therapeutics' higher probable upside, equities research analysts plainly believe Cardiol Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Cardiol Therapeutics had 1 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.61 beat Cardiol Therapeutics' score of 0.00 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CorMedix has a net margin of 45.25% compared to Cardiol Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
CorMedix	45.25%	45.57%	24.76%

CorMedix has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
CorMedix	$400.05M	1.46	$163.05M	$2.13	3.50

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Summary

CorMedix beats Cardiol Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Contineum Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Cardiol Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 488.24%. Contineum Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 36.55%. Given Cardiol Therapeutics' higher probable upside, equities research analysts clearly believe Cardiol Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cardiol Therapeutics has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Contineum Therapeutics	$50M	11.16	-$59.98M	-$1.73	N/A

Cardiol Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 1 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.61 beat Cardiol Therapeutics' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Contineum Therapeutics' return on equity of -24.73% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Contineum Therapeutics	N/A	-24.73%	-23.51%

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Contineum Therapeutics beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Relmada Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

Relmada Therapeutics' return on equity of -59.03% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Relmada Therapeutics	N/A	-59.03%	-53.97%

Cardiol Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 488.24%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 163.45%. Given Cardiol Therapeutics' higher possible upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Cardiol Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Relmada Therapeutics had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 7 mentions for Relmada Therapeutics and 3 mentions for Cardiol Therapeutics. Relmada Therapeutics' average media sentiment score of 0.53 beat Cardiol Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Relmada Therapeutics beats Cardiol Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$167.46M	$11.91B	$7.04B	$12.92B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-5.16	788.55	269.95	24.78
Price / Sales	N/A	968.18	650.49	107.95
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	13.14	10.32	11.25	6.43
Net Income	-$24.20M	$2.77B	$3.45B	$347.27M
7 Day Performance	10.31%	1.96%	3.49%	2.53%
1 Month Performance	43.07%	-1.59%	-0.66%	-1.03%
1 Year Performance	46.57%	191.11%	77.20%	23.28%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	2.242 of 5 stars	$1.45 +1.8%	$8.50 +488.2%	+44.0%	$167.46M	N/A	N/A	20	Upcoming Earnings
ZVRA Zevra Therapeutics	4.3274 of 5 stars	$10.22 +1.6%	$26.86 +162.9%	-3.8%	$604.74M	$106.47M	5.14	20	News Coverage Earnings Report Analyst Forecast Analyst Revision
HELP Cybin	2.3307 of 5 stars	$8.62 +6.9%	$45.25 +425.1%	N/A	$603.26M	N/A	N/A	50
CRMD CorMedix	2.546 of 5 stars	$7.64 +1.2%	$14.86 +94.5%	-28.0%	$598.18M	$311.71M	3.58	30	Positive News Upcoming Earnings
CTNM Contineum Therapeutics	1.6179 of 5 stars	$16.27 +2.1%	$20.25 +24.5%	+132.5%	$593.04M	$50M	N/A	31	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDL) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. ZVRA, HELP, CRMD, CTNM, and RLMD

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Summary

How does Cardiol Therapeutics compare to Cybin?

Summary

How does Cardiol Therapeutics compare to CorMedix?

Summary

How does Cardiol Therapeutics compare to Contineum Therapeutics?

Summary

How does Cardiol Therapeutics compare to Relmada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. ZVRA, HELP, CRMD, CTNM, and RLMD

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Is CRDL or ZVRA more profitable?

Does the media favor CRDL or ZVRA?

Which has more volatility & risk, CRDL or ZVRA?

Do insiders and institutionals believe in CRDL or ZVRA?

Which has higher earnings and valuation, CRDL or ZVRA?

Do analysts recommend CRDL or ZVRA?

Summary

How does Cardiol Therapeutics compare to Cybin?

Which has higher valuation & earnings, CRDL or HELP?

Do insiders & institutionals believe in CRDL or HELP?

Which has more volatility & risk, CRDL or HELP?

Does the media prefer CRDL or HELP?

Do analysts rate CRDL or HELP?

Is CRDL or HELP more profitable?

Summary

How does Cardiol Therapeutics compare to CorMedix?

Do analysts rate CRDL or CRMD?

Does the media favor CRDL or CRMD?

Is CRDL or CRMD more profitable?

Which has preferable earnings and valuation, CRDL or CRMD?

Do insiders and institutionals believe in CRDL or CRMD?

Which has more risk and volatility, CRDL or CRMD?

Summary

How does Cardiol Therapeutics compare to Contineum Therapeutics?

Do analysts recommend CRDL or CTNM?

Which has stronger valuation and earnings, CRDL or CTNM?

Which has more volatility and risk, CRDL or CTNM?

Does the media prefer CRDL or CTNM?

Is CRDL or CTNM more profitable?

Do insiders & institutionals have more ownership in CRDL or CTNM?

Summary

How does Cardiol Therapeutics compare to Relmada Therapeutics?

Which has better earnings & valuation, CRDL or RLMD?

Is CRDL or RLMD more profitable?

Do analysts prefer CRDL or RLMD?

Which has more risk & volatility, CRDL or RLMD?

Do insiders and institutionals have more ownership in CRDL or RLMD?

Does the media prefer CRDL or RLMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools